SIGNIFICANT EVENTS DURING THE FIRST QUARTER
- In January, RaySearch announced that the number of radiotherapy clinics in Japan using RayStation for dose planning has now passed 200. Japan is RaySearch's second largest market in terms of number of clinics. Since its launch in 2009, RayStation has been sold to more than 900 cancer centers worldwide. The most RayStation clinics, roughly 250, are in the USA and in third place, after Japan, is China, where around 80 clinics have RayStation.
SIGNIFICANT events AFTER THE END OF THE REPORTING PERIOD
- In April, RaySearch Laboratories announces that the number of clinics worldwide that have purchased the RayStation for ion radiation therapy dose planning has passed 100. The latest of these customers is Moffitt Cancer Center in Florida, USA, which will add proton therapy dose planning to its existing RayStation infrastructure, which has been in clinical use since 2019.
- On April 26, RaySearch announces preliminary figures for the first quarter of 2023, which mean that RaySearch is in breach of a solvency ratio and an EBITDA-based covenant in the company's unused credit facility with Skandinaviska Enskilda Banken (publ). A waiver has been obtained meaning that the credit facilitites are fully available.
- In May, RaySearch announces that Yonsei Cancer Center in South Korea has treated its first patient where RayStation and RayCare were used for radiotherapy with carbon ions.
- RaySearch announced in May that the strategic partnership with BEBIG Medical, which began in 2018, has been extended through a memorandum of the agreement. BEBIG Medical is a leading global supplier of high-quality radiotherapy products and within the new agreement the companies aim to develop more comprehensive solutions, to achieve more effective treatments and better outcomes. BEBIG Medical is also a distributor for the Chinese company Shinvas linear accelerators and will sell those globally outside of China, equipped with RaySearch software RayStation and RayCare.
CEO Johan Löf and CFO Henrik Bergentoft will present RaySearch’s interim report for January-March 2023 at a webcast to be held in English on Wednesday, May 17, 2023 at 10:00-10:30 a.m. CEST.
Link to webcast: https://raysearchlabs.creo.se/230517
You can also join the webcast by phone:
Sweden +46 8 505 100 31
UK: +44 207 107 06 13
US: +1 631 570 56 13
The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on
May 17, 2023 at 7:45 a.m. CEST.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Henrik Bergentoft, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00